LiDCO Group Plc
07 July 2005


Immediate Release                                                 7th July 2005

                                LiDCO GROUP PLC

                           ("LiDCO" or "the Company")


               New Veterinary Application for LiDCO's Technology

LiDCO Group plc (AIM: LID), the cardiovascular monitoring company, is pleased to
announce the publication of a paper by researchers at the Royal Veterinary
Hospital, London validating LiDCO's LiDCOplus Monitor, and in particular the
Company's pulse contour software (PulseCO),for use in the care of horses during
surgery. The study shows that the software, which is used routinely in humans
for the management of critical care and cardiovascular high risk hospital
patients, is similarly effective in equine applications.


This is the first time that LiDCO's proprietary software, providing continuous
pulse contour cardiovascular monitoring, has been demonstrated to be applicable
in horses.


The paper was entitled: "Use of Lithium dilution and pulse contour analysis
cardiac output determination in anaesthetized horses: a clinical evaluation - G.
Hallowell & K. Corley, Veterinary Anaesthesia and Analgesia, 2005, 32, 201 -
211."


The paper concluded that LiDCO's method of pulse contour analysis is a
relatively non-invasive and reliable way of monitoring continuous cardiac output
in horses under anaesthesia. The paper also concluded that the ability to easily
monitor continuous cardiac output might decrease morbidity and mortality in the
anaesthetized horses.


LiDCO believes that these results are comparable with what the Company has
previously seen from the use of the LiDCOplus technology in humans where the
Company has been able to show that complications, costs and hospital stay can be
reduced by an average of 10 days in high risk surgery patients.


Dr Kevin Corley, lecturer in Equine Medicine and Critical Care at the Royal
Veterinary Hospital, London, stated:


"Lithium dilution cardiac output has proven its worth time and time again in the
care of critically ill horses and foals. The addition of continuous cardiac
output via pulse contour analysis is a fantastic extra, as it allows us to
quickly respond to changes in the haemodynamics of the horse."

Dr Terry O'Brien, LiDCO's Chief Executive, commented:

"Horses are even more sensitive to anaesthetic drugs than humans and can be
severely and adversely affected by the use of such agents during surgery. This
paper further validates the accuracy and utility of our products. The use of
LiDCO's minimally invasive continuous cardiovascular monitoring in veterinary,
practice should lead to a significant reduction in surgical deaths and
complications".

For further information please contact:

LiDCO Group Plc
Terry O'Brien - Chief Executive                        Tel: +44 (0)20 7749 1500
Hugh McGarel-Groves - Finance Director

Buchanan Communications
Tim Anderson, Mary-Jane Johnson, James Strong          Tel: +44 (0)20 7466 5000

Panmure Gordon
Grant Harrison, Marcus Jackson                         Tel: +44 (0)20 7459 3600

Notes for Editors:


About LiDCO Plc


LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of
minimally invasive, computer-based hemodynamic monitoring equipment and
disposables used primarily for the management of critical care and
cardiovascular risk hospital patients. Use of LiDCO's technology has been shown
to significantly reduce the complications (particularly infections) and costs
associated with major surgery.  The technology was invented in the Department of
Applied Physiology based at St Thomas' Hospital, London where the Company
maintains a research base.


The Company's manufacturing facility is in Hoxton, London and its current
products are:


LiDCOplus and PulseCO monitors: computer-based platforms for displaying a range
of real-time, continuous hemodynamic parameters including cardiac output, oxygen
delivery and fluid volume;


LiDCO disposables: used in conjunction with the LiDCOplus Monitor accurately
determine cardiac output in a minimally-invasive manner.


Distribution Network:


The Company has achieved registration for its products in 13 markets across
Europe, the USA, Brazil and Japan.  It sells direct to the NHS in the UK, and
through a worldwide network of specialty critical care distributors.


Background to the recently published clinical trial: Better than standard care -
(EGDT) improves outcome in high risk surgery patients:


The results of a major trial at St George's Hospital, London using LiDCO's
minimally invasive monitoring technology were presented during the 25th
International Symposium on Intensive Care and Emergency Medicine in Brussels
(21st to 25th March). The results have revealed the following:


a) Savings in the cost of treating patients amounting to an average of £4,000
per patient.  Extrapolated nationally, this would equate to a saving of £500
million per annum for the NHS


b) The monetary saving (£248,000) - resulted from 640 hospital days saved for 62
patients, an average of more than 10 bed days per patient


c) The savings in cost and hospital days were associated with a significant
reduction in medical complications (particularly infections - which were halved)
 through the use of LiDCO's minimally invasive technology to improve tissue
oxygen levels following surgery.


                      This information is provided by RNS
            The company news service from the London Stock Exchange